Quetiapine, sold under the brand name Seroquel, is one of the most commonly used medications for delirium in hospitals and intensive care units, yet the evidence behind it is surprisingly thin. Major clinical practice guidelines recommend against the routine use of any antipsychotic, quetiapine included, for treating delirium. The drug persists in practice largely because it can help manage agitation and sleeplessness, and because clinicians often feel they need something while the underlying cause of delirium is being addressed. The gap between how often quetiapine is prescribed and how well it actually works is worth understanding, especially if you or a family member is dealing with delirium in a hospital setting.
How Quetiapine Stacks Up Against Other Antipsychotics
The most common comparison in the research is quetiapine versus haloperidol (Haldol), an older antipsychotic that has been used for delirium for decades. Multiple head-to-head trials have found that the two drugs perform similarly. A randomized trial comparing quetiapine and haloperidol found that by day six, roughly two-thirds of patients in both groups had improved substantially, with no significant difference in delirium scores, cognitive recovery, or sleep time between the groups.1PubMed Central. Comparative effectiveness of quetiapine and haloperidol in delirium: A single blind randomized controlled study A separate double-blind trial reached the same conclusion: delirium severity scores dropped by similar amounts in both groups, and response and remission rates did not differ.2PubMed Central. Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial
A 2025 systematic review and meta-analysis that pooled data across multiple trials confirmed this pattern. Quetiapine and haloperidol showed no statistically significant differences in delirium severity, mortality, sleep time, or overall response rate.3PubMed. Effect of quetiapine versus haloperidol on delirium severity in hospitalized adults: A systematic review and meta‑analysis In other words, quetiapine does not appear to treat delirium better than haloperidol. The main reason clinicians sometimes prefer it is the side-effect profile, not superior effectiveness.
The Bigger Problem With Antipsychotics and Delirium
The question is not just whether quetiapine beats haloperidol. The more important finding, and one that often surprises people, is that antipsychotics as a class have not convincingly outperformed placebo for delirium. A large systematic review covering 16 randomized trials and 10 observational studies of hospitalized adults found no difference in delirium duration, hospital length of stay, sedation status, or mortality between patients given antipsychotics (haloperidol or second-generation drugs like quetiapine) and those given placebo. The review concluded that current evidence does not support the routine use of any antipsychotic to treat delirium in hospitalized adults.4Annals of Internal Medicine. Antipsychotics for Treating Delirium in Hospitalized Adults: A Systematic Review
The 2018 PADIS guidelines from the Society of Critical Care Medicine reflect this evidence directly. They suggest against the routine use of haloperidol or any atypical antipsychotic for delirium treatment in the ICU, noting that the quality of available evidence is low.5Critical Care Medicine. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU That “suggest against” language is not an outright ban. It means the guidelines acknowledge some patients may still be given these drugs on a case-by-case basis, but the default stance is to not use them routinely.
This matters because delirium is extremely common in ICUs and hospital wards, and the instinct to prescribe something is strong. But the evidence keeps pointing toward the same conclusion: antipsychotics manage symptoms like agitation and disruptive behavior, but they do not appear to shorten the delirium itself or improve the outcomes that patients and families care about most.
Situations Where Quetiapine Might Still Be Useful
Despite the lukewarm overall evidence, there are specific scenarios where quetiapine seems to offer real benefit. The drug’s sedative properties, which stem from its strong activity at histamine receptors, make it particularly useful when delirium is accompanied by severe agitation or when disrupted sleep is driving the clinical picture. A narrative review of quetiapine in critical care noted that the drug is often preferred over first-generation antipsychotics precisely because of those sedative effects and a more favorable safety profile, even though guidelines remain cautious about recommending it routinely.6PubMed Central. The Role of Quetiapine in Treating Delirium in Critical Care Settings: A Narrative Review
One area where quetiapine has shown a positive signal is hypoactive delirium, the quieter form where patients are withdrawn, confused, and drowsy rather than agitated. In a retrospective study of critically ill adults, those treated with quetiapine had a shorter duration of hypoactive delirium compared with those who received standard care alone (about one and a half days versus two days). Time to removal from a ventilator also trended in quetiapine’s favor, though that finding didn’t quite reach statistical significance.7Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Impact of Quetiapine Treatment on Duration of Hypoactive Delirium in Critically Ill Adults: A Retrospective Analysis This is noteworthy because hypoactive delirium is frequently underdiagnosed and undertreated, and few interventions have shown much effect on it.
Another setting where quetiapine appears to add value is palliative and end-of-life care. A large observational study of patients with advanced cancer found that quetiapine was one of the factors associated with improvement in delirium symptoms. The study also found that patients with hyperactive or mixed-motor delirium subtypes, better functional status, and longer estimated prognosis were more likely to improve with antipsychotic treatment. Extrapyramidal symptoms and drowsiness were the most common side effects, affecting roughly one in ten patients each.8PubMed. Safety and effectiveness of antipsychotic medication for delirium in patients with advanced cancer: A large-scale multicenter prospective observational study in real-world palliative care settings
There is also some evidence around early pharmacological treatment of delirium helping to reduce the use of physical restraints. One study found that patients who received treatment spent fewer days in restraints compared with untreated patients (about three days versus six) and were extubated sooner.9Annals of Pharmacotherapy. Early Pharmacological Treatment of Delirium May Reduce Physical Restraint Use For families, this can be a meaningful practical benefit even if the overall delirium course is not dramatically shortened.
Safety Concerns Worth Knowing About
One reason quetiapine is favored over haloperidol is cardiac safety, specifically the risk of a dangerous heart rhythm abnormality linked to QT prolongation. All antipsychotics can prolong the QT interval to some degree, and in theory this can trigger a life-threatening arrhythmia called torsades de pointes. In a secondary analysis of a large randomized trial, torsades de pointes occurred twice in the haloperidol group and never among patients receiving other treatments. Ventricular arrhythmias did occur sporadically in various groups, but clinical teams did not attribute them to the study drugs.10JAMA Network Open. Antipsychotics and the QTc Interval During Delirium in the Intensive Care Unit: A Secondary Analysis of a Randomized Clinical Trial
A study looking specifically at quetiapine’s impact on the QT interval in critically ill patients found no significant change from baseline after the drug was given. The average QT change was under three milliseconds, which is clinically negligible. The results were also no different from a comparison group receiving melatonin.11Annals of Pharmacotherapy. Impact of Quetiapine Therapy on QTc Prolongation in Critically Ill Patients This is reassuring, though it does not eliminate the need for monitoring in patients who already have prolonged QT intervals or are on other medications that carry the same risk.
A subtler safety concern involves quetiapine’s metabolite, norquetiapine. Quetiapine itself has limited anticholinergic activity, but once the liver breaks it down, the resulting metabolite norquetiapine binds to muscarinic receptors with moderate to high affinity. This is relevant because anticholinergic drugs are a well-known trigger for delirium. In rare cases, quetiapine has actually been reported to cause or worsen delirium through this mechanism, a paradox that clinicians need to be aware of, especially when using higher doses.12PubMed Central. Delirium Induced by Quetiapine and the Potential Role of Norquetiapine
Risks in Older Patients
Delirium is overwhelmingly a condition of older adults, which creates a tension: the patients most likely to develop delirium are also the patients most vulnerable to the adverse effects of antipsychotics. A real-world study of older patients with delirium found that those who received antipsychotics (with or without the benzodiazepine lorazepam) had worse outcomes than those who received neither drug. Among patients given both an antipsychotic and lorazepam, the trends were starkest, with higher rates of post-discharge institutionalization and in-hospital mortality compared with patients who received no pharmacological treatment for their delirium. The authors cautioned that clinicians should be careful about routinely prescribing these drugs to older patients with delirium.13PubMed Central. Antipsychotics and Lorazepam During Delirium: Are We Harming Older Patients? A Real-Life Data Study
It is important to note that this was an observational study, not a randomized trial. Patients given antipsychotics were likely sicker and more agitated to begin with, which could partly explain the worse outcomes. Still, the signal is consistent with broader concerns about antipsychotic use in elderly populations, including the well-known FDA black-box warning about increased mortality risk in older adults with dementia-related behavioral disturbances. Delirium and dementia frequently overlap, making this warning practically relevant even when quetiapine is being prescribed specifically for delirium.
Why Non-Drug Approaches Come First
If antipsychotics have limited evidence for delirium, what does work? The strongest evidence supports a bundle of non-drug strategies. A recent narrative review in a major anesthesia journal concluded that pharmacological interventions have not shown consistent benefit for preventing or treating delirium, while multicomponent non-pharmacological approaches are associated with a reduced incidence of delirium and improved functional outcomes.14Anaesthesia. Critical care delirium: prevention, identification and management: a narrative review
These strategies are not glamorous, but they have better evidence behind them than any medication:
- Early mobilization: Getting patients moving as soon as medically safe, even if it starts with sitting up in bed.
- Sleep hygiene: Protecting nighttime sleep by reducing noise, dimming lights, and clustering nursing tasks so patients are not woken up every hour.
- Reorientation: Providing clocks, calendars, familiar objects, and consistent communication about where the patient is and what is happening.
- Minimizing sedation: Using the lightest sedation possible and conducting daily interruptions to see if sedation can be reduced or stopped.
- Family engagement: Having family members present to provide familiar voices and faces.
The difficulty, of course, is that these interventions require staffing, time, and coordination. In an understaffed ICU at two in the morning, prescribing quetiapine is faster than implementing a reorientation protocol. This practical reality is a major reason the drug continues to be used despite weak evidence, and it is a legitimate consideration even if it makes the evidence purists uncomfortable.
The Problem of Prescriptions That Follow Patients Home
One of the most underappreciated risks of starting quetiapine for delirium is that the prescription often does not stop when the delirium resolves. A multicenter evaluation across hospitals in New Jersey found that more than half of patients started on antipsychotics for ICU delirium were still on the medication when they transferred out of the ICU, and about 61% were still on it when they left the hospital entirely.15American Journal of Health-System Pharmacy. Descriptive analysis of the unwarranted continuation of antipsychotics for the management of ICU delirium during transitions of care: A multicenter evaluation across New Jersey
A separate study found similar numbers, with about 53% of patients still on antipsychotics at ICU discharge and roughly 21% still on them at hospital discharge. That study also identified quetiapine specifically as one of the strongest independent predictors of continued prescribing, with patients treated with quetiapine nearly six times more likely to be discharged on an antipsychotic than those treated with other agents.16PubMed. Discharge from hospital with newly administered antipsychotics after intensive care unit delirium – Incidence and contributing factors A third study found that about 55% of ICU patients started on atypical antipsychotics were discharged with a prescription to continue the drug.17Therapeutic Advances in Drug Safety. Continuation of atypical antipsychotic medications in critically ill patients discharged from the hospital: a single-center retrospective analysis
This matters because quetiapine carries real long-term risks that are not justified when delirium has resolved. Weight gain, metabolic syndrome, sedation that increases fall risk, and the cardiovascular and mortality concerns in elderly populations all become relevant when a drug prescribed for a short-lived crisis becomes a chronic medication by inertia. If you or a family member leaves the hospital with a quetiapine prescription that was started during an ICU stay, it is worth asking whether the medication is still needed and when a plan to taper it off would begin.
How Dosing and Timing Are Handled in Practice
Quetiapine for delirium is typically given at low doses compared with its use in psychiatric conditions like schizophrenia or bipolar disorder. Starting doses in the ICU commonly range from 12.5 to 50 milligrams, with upward adjustments depending on symptom control. The drug comes only in oral or feeding-tube form, which is a practical limitation for patients who cannot swallow. Haloperidol, by contrast, can be given intravenously, which is one reason some ICU teams still reach for it first in emergencies.
Whether quetiapine should be dosed at bedtime only or given twice daily is a question clinicians often ask. A retrospective study comparing the two approaches found no significant differences in ICU or hospital length of stay, duration of mechanical ventilation, delirium recovery rates, in-hospital death, or QT prolongation between patients given quetiapine twice daily and those given it at bedtime.18Journal of Pharmacy Practice. Quetiapine Twice Daily Versus Bedtime Dosing in the Treatment of ICU Delirium Bedtime-only dosing takes advantage of the drug’s sedative effect to help normalize the sleep-wake cycle, which is often severely disrupted during delirium. Some clinicians prefer this approach precisely because it avoids daytime sedation that could interfere with early mobilization and participation in physical therapy.
Ongoing Research and Unanswered Questions
Much of the existing research on quetiapine for delirium is limited by small sample sizes, inconsistent definitions of delirium subtypes, and the sheer heterogeneity of critically ill populations. A major ongoing trial called CALM-ICU is attempting to address one important gap by comparing quetiapine head-to-head with olanzapine, another atypical antipsychotic, in critically ill patients with hyperactive delirium. The trial is designed to enroll roughly 1,200 patients across multiple sites, measuring delirium-free and coma-free days as the primary outcome.19PubMed Central. Olanzapine versus quetiapine in critically ill patients with hyperactive delirium: Protocol for a multicentre, cluster-randomised, double-crossover, pragmatic clinical trial (CALM-ICU) This is the kind of large pragmatic trial the field has needed, because so many existing studies are too small to detect meaningful differences.
The broader tension in delirium research is that the condition itself is a symptom of something else gone wrong, whether that is infection, organ failure, medication toxicity, or metabolic derangement. Treating the symptom with an antipsychotic without fixing the underlying cause is a bit like putting ice on a broken bone. The ice may help with the pain, but it is not setting the fracture. Future research is likely to focus less on which antipsychotic is best and more on identifying subgroups of patients who might genuinely benefit from pharmacological treatment, particularly those whose agitation creates immediate safety risks or whose suffering is otherwise unmanageable. For patients with advanced illness and limited time, the calculus is different from a post-surgical ICU patient who is expected to recover fully. The evidence from palliative care settings already suggests that these are different clinical problems that may warrant different approaches.
One practical question that remains underexplored is whether early use of quetiapine can prevent delirium from developing in the first place. A small prophylaxis study in high-risk critically ill patients found that quetiapine significantly reduced ventilator duration compared with controls.20PubMed. Quetiapine for delirium prophylaxis in high-risk critically ill patients That is an intriguing finding, but it comes from a single small study and has not been replicated at scale. Prevention trials are logistically harder than treatment trials because you need to enroll many patients who might never develop delirium, making them expensive and slow. Until larger prevention studies are completed, quetiapine’s role in prophylaxis remains speculative.